Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy

被引：17

作者：

Guilloton, L. ^{[1
]}

Pegat, A. ^{[1
]}

Defrance, J. ^{[1
]}

Quesnel, L. ^{[1
]}

Barral, G. ^{[2
]}

Drouet, A. ^{[1
]}

机构：

[1] HIA Desgenettes, Serv Neurol, 108 Blvd Pinel, F-69275 Lyon 03, France

[2] Cabinet Gynecol, 12 Chem Croix Pivort, F-69110 St Foy Les Lyon, France

来源：

JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION | 2017年 / 46卷 / 03期

关键词：

Multiple sclerosis; Pregnancy; Natalizumab;

D O I：

10.1016/j.jogoh.2017.02.008

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Natalizumab is a monoclonal antibody indicated for the treatment of patients with relapsing-remitting multiple sclerosis. Its use is prohibited during pregnancy. However, natalizumab exposures throughout the gestation period or during the third trimester, because of intense disease activity, are possible and begin to be reported. There are enough reassuring arguments against a teratogenicity, through pregnancy registries; but deleterious effects in the monitoring of newborn, are not well known. A disorder of hematopoiesis is possible with anemia, thrombocytopenia or pancytopenia, as discussed by the author through an observation. These hematological disorders seem to be asymptomatic; they resolve spontaneously and require a simple biological and clinical monitoring of the newborn. (C) 2017 Elsevier Masson SAS. All rights reserved.

引用

页码：301 / 302

页数：2

共 10 条

[1] Extended interval dosing of natalizumab: a two-center, 7-year experience [J].

Bomprezzi, Roberto ;

Pawate, Siddharama .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2014, 7 (05) :227-231

[2]

Cachia D, 2014, BMJ CASE REP, V30

[3] Natalizumab throughout pregnancy: Risk of low platelet count in the newborn at delivery [J].

Ciron, J. ;

Hautecoeur, P. ;

Mathis, S. ;

Neau, J. -P. .

REVUE NEUROLOGIQUE, 2016, 172 (02) :165-166

[4]

CRISTIANO L, 2013, NEUROLOGY S, V80

[5] How safe is natalizumab during pregnancy? [J].

Duquette, Pierre ;

Prat, Alexandre .

MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (02) :121-122

[6] Normal outcome of pregnancy with ongoing treatment with natalizumab [J].

Fagius, J. ;

Burman, J. .

ACTA NEUROLOGICA SCANDINAVICA, 2014, 129 (06) :E27-E29

[7] Natalizumab Use During the Third trimester of Pregnancy [J].

Haghikia, Aiden ;

Langer-Gould, Annette ;

Rellensmann, Georg ;

Schneider, Henriette ;

Tenenbaum, Tobias ;

Elias-Hamp, Birte ;

Menck, Sylvia ;

Zimmermann, Julian ;

Herbstritt, Sandra ;

Marziniak, Martin ;

Kuempfel, Tania ;

Meinl, Ingrid ;

Plavina, Tatiana ;

Gold, Ralf ;

Hellwig, Kerstin .

JAMA NEUROLOGY, 2014, 71 (07) :891-895

[8] Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases [J].

Hoevenaren, I. A. ;

de Vries, L. C. ;

Rijnders, R. J. P. ;

Lotgering, F. K. .

ACTA NEUROLOGICA SCANDINAVICA, 2011, 123 (06) :430-433

[9] Extended interval dosing of natalizumab in multiple sclerosis [J].

Ryerson, L. Zhovtis ;

Frohman, T. C. ;

Foley, J. ;

Kister, I. ;

Weinstock-Guttman, B. ;

Tornatore, C. ;

Pandey, K. ;

Donnelly, S. ;

Pawate, S. ;

Bomprezzi, R. ;

Smith, D. ;

Kolb, C. ;

Qureshi, S. ;

Okuda, D. ;

Kalina, J. ;

Rimler, Z. ;

Green, R. ;

Monson, N. ;

Hoyt, T. ;

Bradshaw, M. ;

Fallon, J. ;

Chamot, E. ;

Bucello, M. ;

Beh, S. ;

Cutter, G. ;

Major, E. ;

Herbert, J. ;

Frohman, E. M. .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (08) :885-889

[10] Postnatal Development in Cynomolgus Monkeys Following Prenatal Exposure to Natalizumab, an α4 Integrin Inhibitor [J].

Wehner, Nancy G. ;

Shopp, George ;

Osterburg, Ingrid ;

Fuchs, Antje ;

Buse, Eberhard ;

Clarke, Janet .

BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2009, 86 (02) :144-156

← 1 →